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Abstract
Background: Islet cell transplantation is a method to stabilize type 1 diabetes patients with hypoglycemia unawareness
and unstable blood glucose levels by reducing insulin dependency and protecting against severe hypoglycemia through
restoring endogenous insulin secretion. This study analyses the current cost-effectiveness of this technology and
estimates the value of further research to reduce uncertainty around cost-effectiveness.
Methods: We performed a cost-utility analysis using a Markov cohort model with a mean patient age of 49 to simulate
costs and health outcomes over a life-time horizon. Our analysis used intensive insulin therapy (IIT) as comparator and
took the provincial healthcare provider perspective. Cost and effectiveness data for up to four transplantations per patient
came from the University of Alberta hospital.
Costs are expressed in 2012 Canadian dollars and effectiveness in quality-adjusted life-years (QALYs) and life years. To
characterize the uncertainty around expected outcomes, we carried out a probabilistic sensitivity analysis within the
Bayesian decision-analytic framework. We performed a value-of-information analysis to identify priority areas for future
research under various scenarios. We applied a structural sensitivity analysis to assess the dependence of outcomes on
model characteristics.
Results: Compared to IIT, islet cell transplantation using non-generic (generic) immunosuppression had additional
costs of $150,006 ($112,023) per additional QALY, an average gain of 3.3 life years, and a probability of being cost-
effective of 0.5 % (28.3 %) at a willingness-to-pay threshold of $100,000 per QALY. At this threshold the non-generic
technology has an expected value of perfect information (EVPI) of $260,744 for Alberta. This increases substantially in
cost-reduction scenarios. The research areas with the highest partial EVPI are costs, followed by natural history, and
effectiveness and safety.
Conclusions: Current transplantation technology provides substantial improvements in health outcomes over
conventional therapy for highly selected patients with ‘unstable’ type 1 diabetes. However, it is much more costly and
so is not cost-effective. The value of further research into the cost-effectiveness is dependent upon treatment costs.
Further, we suggest the value of information should not only be derived from current data alone when knowing that
this data will most likely change in the future.
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Background
Islet cell transplantation is a method for stabilizing cer-
tain type 1 diabetes (T1DM) patients with hypoglycemia
unawareness and unstable blood glucose levels [1, 2].
For these patients conventional management with inten-
sive insulin therapy can be life-threatening [3]. In allo-
geneic islet cell transplantation the islets, isolated from
deceased donors, containing glucose-responsive insulin-
producing beta cells, are transplanted to replace the pa-
tient’s own beta cells, previously destroyed by the
chronic autoimmune disease T1DM [3–5]. This treat-
ment has substantially improved the lives of patients, by
reducing glycemic lability, risk of severe hypoglycemia,
so-called “death-in-bed events”, long-term cognitive and
physical disability, and in many cases has led to decrease
or discontinuation of exogenous insulin therapy for vari-
able periods of time [6–8].
In July 2000 the Edmonton protocol for islet cell trans-
plantation, developed at the University of Alberta Hospital
(Edmonton, Canada), reported promising results of
achieving sustained insulin independence in seven con-
secutive patients [4]. However, five-year insulin inde-
pendence rates were only about 10 % [9]. Substantial
refinements of transplant procedure and immunosup-
pression regimen, have led to insulin independence
rates of 60 % at four years and 50 % at five years, rates
that now match those results obtained by whole pan-
creas transplantation [2, 8, 10, 11]. Further, graft sur-
vival, the main factor in protection against severe
hypoglycemia, is 82 % at five years [8, 9]. Of the 166
patients that had islet cell transplantations at the
University of Alberta Hospital between 1999 and July
2012, 79 % still had graft survival in 2012 and therefore
protection from severe hypoglycemia [2]. Graft survival
was defined here, in agreement with Barton and col-
leagues, as having either full graft function (independ-
ence from exogenous insulin for ≥14 consecutive days)
or partial graft function (no insulin independence, but
with C-peptide secretion ≥0.3 ng/mL) [8].
Between 120,000 and 300,000 Canadians have T1DM
[12–14]. Of these about 10 % are especially sensitive to
insulin and have defective counter-regulatory hormonal
responses, putting them at higher risk of neuroglycope-
nia due to severe hypoglycemia [15]. Additionally, up
to 10 % of T1DM mortality is due to hypoglycemia
[16, 17]. Consequently, between 15,000 and 30,000
Canadian patients could potentially benefit from islet
cell transplantation. However, patients must meet ex-
tensive eligibility criteria, including absence of: signifi-
cant renal impairment, active infection (tuberculosis,
HIV), desire for fertility, malignancy, thrombophilia
or coagulopathy, substance abuse, insulin require-
ments of > 1.0 u/kg/day, and severe or untreated car-
diac disease [2]. Additionally, there are many barriers
to the widespread adoption of islet cell transplant-
ation, including limited donor availability and the
risks of post transplant immunosuppression [18].
The purpose of our study was to evaluate the cost-
effectiveness of allogeneic islet cell transplantation, as
provided at the University of Alberta Hospital. We com-
pared the costs and benefits of allogeneic islet cell trans-
plantation and intensive insulin therapy in transplant
eligible patients. Our study was conducted from the per-
spective of the provincial health care payer (Alberta
Health Services), using the patterns of care and costs ob-
served at the University of Alberta Hospital. In addition,
we examined the value of further research to reduce
current uncertainties in the evidence to inform future
reimbursement decisions.
Methods
Our analysis was performed within a Bayesian decision-
analytic framework using stochastic modelling tech-
niques. We used a discrete state-transition Markov
model to simulate marginal differences in clinical effects
and costs, resulting from the two treatment alternatives.
The population was a hypothetical cohort of patients
who met the transplantation inclusion criteria and have
the below defined characteristics. We followed current
best practice modeling guidelines [19–21]. Our methods
for characterising the value of further research were
built upon those previously described by Hall and
colleagues [22].
Treatments compared
Intensive insulin therapy (IIT) is variable but involves a
form of frequent self-monitoring of blood glucose and
three or more daily insulin injections, or equivalent ther-
apy with an insulin pump. IIT generally includes the use
of a long acting basal insulin (e.g., glargine or detemir)
and multiple doses of short acting insulin (e.g., glulisine,
aspart, lispro), with highly variable dosage, usually 0.6 u/
kg/day. In our model, we simulated mean results of ei-
ther best manual or device-based injection and monitor-
ing, plus adherence to behavioural recommendations for
hypoglycemia unawareness.
In contrast to IIT, islet cell transplantation is per-
formed via injection into the liver with on average 5783
islet equivalents per kg for each procedure [2, 9]. Im-
munosuppression is necessary for as long as there is
graft survival. External insulin injections are only needed
when graft survival decreases and partial insulin depend-
ence recurs. The medication used as of 2012 is sum-
marised in Table 1. Generic and non-generic medication
was assumed to be equally effective. We excluded other
treatments involving pancreas and/or kidney transplant-
ation as comparators because their medical risk-benefit
ratio was considered to be too high for patients with our
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Table 1 Cost parameters (in 2012 Canadian dollar per patient)
Source of costs Mean SD RSD Distribution Hyperparameters Sourcea
Pre-transplant visit 569 University of Alberta Hospital
Transplantation (including initial medication,
based on 4 day stay: 1 pre-op and 3 post-op)
91,414 15.0 % Log-Normal μ = 11.412029 University of Alberta Hospital
σ = 0.149166
Total costs per transplantation (including all
costs in the 23 days after a transplantation)
94,765 (via input)
Medication and follow-up (from day 4 post-op onward)
Tacrolimus (per month) 450 7.5 % Log-Normal μ = 6.106443 University of Alberta Hospital
σ = 0.074895
Mycophenolate mofetil (MMF; per month) 500 7.5 % Log-Normal μ = 6.211803 University of Alberta Hospital
σ = 0.074895
Alemtuzumab (once per transplant)b 0 University of Alberta Hospital
Basiliximab (once at 2nd transplant for about
half of patients instead of Alemtuzumab)
3000 University of Alberta Hospital
Valganciclovir (for 14 weeks) 5000 375 7.5 % Log-Normal μ = 8.514389 University of Alberta Hospital
σ = 0.074895
Anakinra (total for remaining 3 days after
discharge)
574 43 7.5 % Log-Normal μ = 6.349825 University of Alberta Hospital
σ = 0.074895
Immunosuppression (per cycle, drugs: see
above)
713 53 7.5 % Log-Normal μ = 6.56667 Calculated via data from University
of Alberta Hospital
σ = 0.074895
Generic immunosuppression (per cycle) 238 18 7.5 % Log-Normal μ =5.46808 Calculated as 1/3 of cost above
(price reduction for generic version
based on market prices)σ = 0.074895
Costs for insulin therapy in graft survival
state (per cycle)
64 (via input) Calculated via data from [33] and
based on [10] as 40 % of costs with
intensive insulin therapy
Post-transplant check-up visit (at week 1, 2,
at 6 months and 1 year and then once a year)
556 42 7.5 % Log-Normal μ = 6.31800 University of Alberta Hospital
σ = 0.074895
Total per cycle (per year) costs for immunosuppression, follow-up and insulin (if applicable)
Full graft function for the first 6 months 1886 (30,175) (via inputs) Calculated via data from University
of Alberta Hospital
Full graft function after the first 6 months 747 (11,956) (via inputs) Calculated via data from University
of Alberta Hospital
Partial graft function for the first 6 months 1950 (31,196) (via inputs) Calculated via University of Alberta
Hospital data and [33]
Partial graft function after the first 6 months 811 (12,977) (via inputs) Calculated via University of Alberta
Hospital data and [33]
Intensive insulin therapy
Average healthcare costs of treating people with newly diagnosed diabetes (first 10 years) per cycle (per year)
Without complications for type 1 and 2
diabetes
159 (2552) 12 7.5 % Log-Normal μ = 5.06920 Corrected data from [33]
σ = 0.074895
With complications for type 1 and 2 diabetes 602 (9632) 120 20.0 % Gamma α = 25.00000 Calculated from corrected data in [33]
β = 24.0796
Other costs (per occurrence)
Average extra costs of initial
immunosuppressive or other complications
600 180 30.0 % Gamma α = 11.1111 Assumption based on [2] and expert
opinion
β = 54.0000
Average extra costs of major
immunosuppressive complications
6500 1300 20.0 % Gamma α = 25.0000 Assumption based on [2] and expert
opinion
β = 260.0000
Bold values were directly used as model inputs and for calculating mean, standard deviation (SD) and relative standard deviation (RSD; i.e., SD as percentage of
the mean). Other values are rounded and were incorporated into bold values. Superscripts: a Source relates to mean values. SD values were the authors’
estimations due to lack of data. b At the time of our study it was provided at no charge through a compassionate release program
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baseline characteristics, largely due to the risks associ-
ated with major surgery [8, 18].
Baseline patient characteristics
Based on findings in two studies we defined the follow-
ing baseline characteristics [2, 23]. Additional to fulfill-
ing the eligibility criteria above, we assumed 55 % of our
cohort to be female, on average 47 years old, with a
diabetes duration of 29.4 (standard deviation = 11.3)
years, a weight of 71.1 (11.8) kg, a BMI of 24.8 (3.1), a
glycated haemoglobin level of 8.2 % (1.3 %), insulin
requirements of 0.6 (0.17) u/kg/day, and only minor to
moderate comorbidities [2].
Perspective
The analyses are presented from the perspective of the
health care payer. Therefore, we considered only health
effects for the patients, and only direct costs faced by
the healthcare provider for those patients. Effectiveness
is expressed in quality-adjusted life-years (QALYs) in
order to measure the impact of therapy on both quality
of life (QOL) and life expectancy. Secondary analyses
using life years are also reported. All costs are measured
in 2012 Canadian dollars, with necessary adjustments
made using the Canadian consumer price index for
health and personal care [24]. Not included in this
analysis are costs falling on the patient’s family and the
impact of health problems on economic activity (prod-
uctivity costs).
Model structure
Cycle length was one-sixteenth of a year (~23 days) with
a time horizon of 1000 cycles (62.5 years). Cycle length
was chosen following consultation with clinical experts,
to allow for the appropriate characterisation of the clin-
ical follow-up of transplant patients, including repeat
transplantations. Although some patients have received
additional transplantations following extremely late graft
failure [25], these cases are very rare and so are not in-
cluded in the model structure. All patients entered the
model at the same time and our time horizon covered
their remaining lifetime.
Transplantation arm
The transplantation arm had six states (Fig. 1): trans-
plantation, insulin independent with full graft survival,
partial graft survival and insulin dependent, IIT without
complications, IIT with diabetes-related complications
and dead. Each patient could have up to four transplan-
tations. All patients started in Transplantation from
where they could move to Insulin independent, Partial
graft survival, IIT with diabetes related complications
and – as from all states – to Dead. Patients could not
move directly from Transplantation to IIT without
complications. Due to the strict eligibility criteria all
transplant patients were assumed to have at least some
initial graft survival unless they experienced diabetes-
related complications.
Patients in the Insulin independent state could remain
in this state or move to Partial graft survival and to one
Fig. 1 Summary model structure (simplified). The transplantation arm includes all six states. In contrast, the comparator arm only includes the
Intensive Insulin Treatment states with and without diabetes-related complications and the Dead state
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of the IIT states (with or without complications). The
Insulin independence state could be entered from the
transplantation state only.
Patients could enter Partial graft survival only from
the Transplantation or Insulin independent states. Re-
transplantation was an option only for patients in Partial
graft survival. In the first six months patients in partial
graft survival state were either re-transplanted or moved
to IIT with or without complications. After the first six
months they could now either remain in Partial graft
survival or move to IIT with or without complications.
Patients in IIT without complications could stay there or
move to IIT with complications. Patients in IIT with
complications could only remain there or move to Dead.
The comparator arm
The comparator arm had the IIT states with and without
complications, and Dead. These were the same states as
in Fig. 1 but without the Transplantation, Insulin inde-
pendent and Partial graft survival states. The costs,
utilities and transition probabilities for these states were
presumed to be the same as for the corresponding states
in the transplantation arm.
Modelling of complications
Our model included three groups of complications: 1)
initial transplant or immunosuppressive-related compli-
cations within the Transplant state, 2) subsequent major
immunosuppressive-related complications within the
graft survival states, and 3) diabetes-related complica-
tions without graft function as a separate state. We
modelled the first two complications as being a weighted
part of the relevant state costs and utilities. This was
similar to our approach for the complications state
where the model structure has been simplified by aggre-
gating serious diabetes complications, additional to the
baseline characteristics, into a single state. Modelling all
of the different complications and combinations of those
complications would have made the model substantially
more complex, likely requiring some form of patient
level simulation. Given the primary health benefit of islet
cell transplantation is the reduction in the risk of
hypoglycemia associated mortality, this aggregation of
other diabetes related complications was judged to be
an acceptable simplification by the clinical experts,
unlikely to substantially affect the assessment of the
therapy’s value.
We used the term diabetes-related complications (DRC)
as meaning diabetes-related complications worse than at
baseline and additional to hypoglycemia unawareness.
Patients from all alive states could get DRC, in which case
immunosuppression had to be ended. There was no
evidence to support the differential modelling of DRC
profiles for IIT patients and transplant patients after graft
failure, although the clinical expectation is that the
time to complications will be delayed for transplant
patients [2, 26–31].
In both treatment arms the same DRC occurred,
but patients with graft survival were at lower risk.
The risks of initial or major immunosuppressive com-
plications were the same for patients with full and
partial graft function. Patients with immunosuppres-
sive complications that were to difficult to treat while
on immunosuppression had to end that medication
and their graft failed.
Parameter estimation and implementation
The following subsections describe the probability, cost
and utility inputs of our model. We assigned distribu-
tions to most parameters (Tables 1, 2 and 3). Further
information about the choice of distributions can be
found in Appendix 1 (Additional file 1).
Event probabilities
Patient life expectancy is a function of the transition
probabilities over the time horizon of the model. Due to
data limitations, all probabilities were assumed to be
constant over all cycles within each of the simulations,
except when directly concerning transplantations or
background mortality. While the probabilities for initial
transplant success and initial complications could be dir-
ectly implemented, the majority of probabilities had to
be calibrated to match source data (e.g., graft survival)
due to ‘competing risk’ bias [32]. The following four
sections and Table 4 provide details on the probabilities
that were implemented in the model.
Treatment effectiveness
The primary goals of islet cell transplantation are to
avoid hypoglycemia and achieve excellent glycemic
control [2]. Insulin independence is also a goal, albeit
secondary, and it increases the probability of long-
lasting graft survival. Another effect of islet cell trans-
plantation is a reduction in DRC [2, 26–31]. We
assumed all alive patients without DRC have some graft
survival in the cycle after transplantation, because al-
most all patients become c-peptide positive after the first
transplantation. The proportion of patients with full
graft function after transplantation, assumed to be in-
creasing from first to third and fourth transplantation,
was based on published data [23] and on expert opinion
that most patients become insulin independent after the
second transplantation. Transition probabilities for graft
loss and recurrence of insulin independence were cali-
brated to achieve the five-year rates (50 % full and 82 %
overall graft survival). To simulate the occasional ineffect-
iveness of the treatment, our model presumed a higher
rate of early graft failure over the first six months.
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Diabetes-related complications
An Ontario study found that 40 % of all diabetes
patients get DRC [33]. Our patient population had up to
moderate comorbidities and unstable T1DM, a complica-
tion in itself which can cause more severe complications
including long-term disability through neuroglycopenia
[15]. Therefore, we made the assumptions that our pa-
tients’ risks of getting other additional DRC are 55 % over
the model horizon and that those risks are reduced by
75 % (55 %) when having full (partial) graft function. The
risk reductions were implemented through hazard ra-
tios and after graft failure, risks returned to non-
transplantation levels.
Mortality
We combined age-specific background mortality rates
in Alberta from female and male life tables [34], using
an age-specific weighted mean (55 % female). Then we
modeled differences in life expectancy between our
patient population and the general non-diabetic popula-
tion. A publication reported a difference in life expect-
ancy of 6.5 years between Canadians with and without
diabetes at our cohort age (77.7 versus 84.2 years total)
[35]. This difference is dominated by the majority of pa-
tients who have type 2 diabetes. Although T1DM is con-
sidered to have a comparatively higher life-expectancy
impact of up to 15 years [14], published data on the
magnitude was scarce. Due to the characteristics of
our patients, we assumed a 12-year difference for our
IIT-treated patients, resulting in a life expectancy of
72.2 years total.
This difference was implemented with two-step in-
creased hazard ratios of mortality in non-graft-survival
states, compared to background mortality. For graft sur-
vival we took background mortality since there was no
evidence of increased mortality due to islet cell trans-
plantation [2]. Of the two data sources for background
mortality only one reported diabetes and non-diabetes
Table 2 Utilitiy weights and disutility parameters (annual)
Condition Weight Disutility
(Decrement)
SD RSD Distribution Hyperparameters Sourcea
Type 1 diabetes (T1DM) no
complicationsb
0.81 0.01 [38, 39]
Full graft function no
complicationsc
0.82 [Base value] 0.041 5 % Beta α = 70.56 T1DM no complications plus “no-injection bonus”
minus immunosuppression disutility (assumptions)
β = 15.48
Partial graft function no
complications




0.71 0.11 (0.10) 0.020 20 % Gamma α = 25.00 Assumption based on [44]
β = 0.004
Diabetes-related complications (additional to hypoglycemia unawareness)
Amputation 0.60 0.22 Assumption based on [39, 47]
Blindness or severe vision
loss
0.63 0.19 Assumption based on [39, 47]
Nephropathy 0.47 0.35 Assumption based on [47]
Heart failure 0.55 0.27 Assumption based on [45]
Stroke 0.49 0.33 Assumptions based on [46]
Myocardial infarction 0.49 0.33
Angina pectoris 0.62 0.20
Aggregated diabetes-
related complications
0.57 0.25 (0.14) 0.042 30 % Gamma α = 11.11 Weighted mean of 7 complications above
with frequency data from [33] minus 0.03
to account for multiple complication casesβ = 0.0126
One-time disutilities (per occurrence)
Initial immunosuppressive
or other complications





X-0.10 0.10 0.025 25 % Gamma α = 16.00 Assumption based on [2] and expert opinion
β = 0.00625
Bold values were directly used as model inputs and for calculating mean, standard deviation (SD) and relative standard deviation (RSD; i.e., SD as percentage of
the mean). Other values are rounded and were incorporated into bold values. Superscripts: a Source relates to mean values. SD values were the authors’
estimations due to lack of data. b All other conditions also included type 1 diabetes and where applicable hypoglycemia unawareness. c From this value the
corresponding disutility increments of the other conditions were subtracted
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Table 3 Probability and ratio parameters
Parameter Mean SD RSD Distribution Hyperparameters Sourcea
Ratio of patients having initial
complications
0.650 0.0650 10 % Beta α = 34.30 Assumption based on [2]
and expert opinion
β = 18.47
Ratio of patients being insulin independent 23 days after the latest transplantation
For the 1st transplantation 0.150 0.0375 25 % Beta α = 13.45 Assumption based on [23]
and expert opinion
β = 76.21
For the 2nd transplantation 0.700 0.1050 15 % Beta α = 12.63 Assumption based on [23]
and expert opinion
β = 5.41
For the 3rd and 4th transplantation (each) 0.850 0.0355 15 % Beta α = 5.80 Assumption based on [23]
and expert opinion
β = 1.02
Hazard ratio (HR) of getting diabetes-related complications
For patients with partial graft function 0.450 0.0675 15 % Log-Normal μ = -0.8096 Assumption based on [2]
σ = 0.149166
For patients with full graft function 55.56 % of HR with
partial graft function
(i.e., 0.25)
0.0840 15 % Log-Normal μ = -0.59891 Assumption based on [2]
σ = 0.149166
Recurrence of insulin dependency per cycle
Probability of becoming partially
dependent for patients with full
graft function
0.0077379 0.001161 15 % Beta α = 44.09 Calculated from [2] and
expert opinion
β = 5653.02
Probability of graft failure for patients with
full graft functionb
0.0000164732 0.00000247 15 % Beta α = 44.44 Calculated from [2] and
expert opinion
β = 2,697,667
Probability of graft failure within the first
six months for patients with partial
graft functionb
0.045 0.00675 15 % Beta α = 42.40 Assumption based on [23]
and expert opinion
β = 899.81
Probability of graft failure after the first six
months for patients with partial
graft functionb




Probability of complications per cycle (over model horizon)
Major immunosuppressive-related 0.00006201 (0.015) 0.000009302
(0.00225)
15 % Beta α = 44.44 Assumption based on [2]
and expert opinion
β = 716,613.00
Ratio of above that are have to end
immunosuppression
0.100 0.015 Beta α = 39.90 Assumption based on
expert opinion
β = 359.10
Additional diabetes-relatedc 0.0018185 (0.55) 0.000364
(0.0825)
20 % Beta α = 24.96 Assumption based on [33]
β = 13,700.60
Mortality (probability of death)
Background all-cause mortality (Age-specific) Fixed Weighted mean of [34]
fitted to match [35]
Hazard ratio (HR) of mortality due
to hypoglycemia
2.40 0.24 10 % Log-Normal μ = 0.870494 Assumption based on
[14, 16, 17, 35] and expert
opinionσ = 0.099751
HR of mortality due to diabetes-related
complications
298.45 % of HR with
only hypoglycemia
(i.e., 7.16)
29.85 10 % Log-Normal μ = 1.088457 Assumption based on
[14, 16, 17, 35] and expert
opinionσ = 0.099751
Bold values were directly used as model inputs and for calculating mean, standard deviation (SD) and relative standard deviation (RSD; i.e., SD as percentage of
the mean). Other values were incorporated into bold values. Most per-cycle values were used in several states and therefore do not sum up to annual or model
horizon values. Superscripts: a Source relates to mean values. SD values were the authors’ estimations due to lack of data. b Meaning graft failure that is not due
to ending immunosuppression because of major immunosuppressive complications. c For patients that did not get an islet transplantation or patients with graft
failure after islet transplantation
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populations separately. To use both sources, we fitted
the all-population life table values from Statistics Canada
to make them consistent with the published life expect-
ancy estimate for the non-diabetes population (see
Appendix 3 in Additional file 1).
Treatment and immunosuppressive complications
Immunosuppressive medication can lead to a range of
complications with substantial variation in their severity.
Although islet cell transplant can be considered minim-
ally invasive and non-surgical when compared to whole
organ transplantation, there are potential complications
associated with the transplant procedure itself [2]. We
assumed 65 % of the patients experience minor initial
complications, which can be overcome within one cycle
e.g., by adapting medication [2]. Based on expert opinion
we assumed that 1.5 % of patients get major immuno-
suppressive complications and 10 % of them have to
stop immunosuppression as a result. As a simplification,
both these complications were implemented into the
model as variables of the overall transition probabilities,
state costs and utilities.
Costs
On the one hand islet cell transplantation causes cost
savings from reduced DRC and to a smaller degree insu-
lin therapy [10]. On the other hand it induces additional
costs from organ procurement, islet processing, the
transplantation procedure itself, follow-up visits, im-
munosuppression and possibly treatment of complica-
tions [2]. We obtained cost data from the University of
Alberta hospital (Chris Broscheit via Mike Bentley, per-
sonal communication, October 12, 25 and November 6,
2012). The provincial healthcare provider covers costs
for procedures, initial drugs and, through a specialized
high cost drug program, immunosuppression [36].
Resource use for the graft survival states consisted of:
immunosuppression, clinical follow-up, insulin therapy
and other medication. (Table 1). We assumed the price
of generic immunosuppressant drugs to be a third of the
Table 4 Main results for different scenarios ordered by life expectancy assumptions (means per patient)













Structural scenarios with difference in LE = 12 yearsa
1 5 % discount rate (base case) $56,560 $347,377 $290,816 9.59 11.52 1.94 $150,006
2 3.5 % discount rate $67,363 $369,647 $302,284 11.14 13.51 2.37 $127,278
3 3 % discount rate $71,695 $378,532 $306,837 11.76 14.31 2.56 $120,008
4 Undiscounted $109,303 $455,743 $346,440 17.08 21.36 4.28 $80,917
5 5 % discount rate; life years $56,560 $347,377 $290,816 14.08 15.12 1.05 $278,188
6 Undiscounted; life years $109,303 $455,743 $346,440 25.30 28.63 3.33 $104,177
7 Undiscounted; double disutilities $109,303 $455,743 $346,440 14.29 19.86 5.56 $62,254
8 Generic Imm.b $56,560 $273,741 $217,180 9.59 11.52 1.94 $112,023
9 Generic Imm.b; 1 % discount rate $94,062 $320,265 $226,203 14.93 18.48 3.55 $63,668
10 Generic Imm.b; each transplantation costs $20,000
less
$56,560 $231,843 $175,283 9.59 11.52 1.94 $90,412
11 Increased costs in IIT (110 %) and DRC (125 %) states $66,426 $352,527 $286,100 9.59 11.52 1.94 $147,573
12 As row above but undiscounted and doubled
disutilities in IIT and DRC states
$129,361 $468,444 $339,083 14.29 19.86 5.56 $60,932
Structural scenarios with difference in LE = 10 yearsa
13 5 % discount rate $60,863 $349,993 $289,130 9.93 11.73 1.80 $160,394
14 3 % discount rate $78,527 $382,868 $304,341 12.30 14.66 2.36 $128,877
15 Undiscounted; life years $123,916 $465,610 $341,694 27.20 29.94 2.74 $124,804
Structural scenarios with difference in LE = 14 yearsa
16 5 % discount rate $51,693 $344,471 $292,778 9.22 11.31 2.09 $140,095
17 3 % discount rate $64,301 $373,931 $309,630 11.20 13.96 2.77 $111,867
18 Undiscounted; life years $94,621 $446,014 $351,393 23.43 27.36 3.93 $89,402
All scenarios used the base case assumptions with the described structural deviations. Benefit measure is QALY unless noted otherwise. All result numbers are
rounded and including sampling variation. Superscripts: a The assumed difference in life expectancy (LE) caused by hypoglycemia unawareness compared to the
non-diabetes population used in the model. b This scenario assumes generic version immunosuppression
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branded price, based on 2014 online market prices of
generic versions available in Canada. To account for the
need of exogenous insulin in some patients who received
beta cell transplants, we added 40 % and 16 % of the IIT
costs to the costs in our Partial graft function and
Transplantation states correspondingly. The costs of ini-
tial and major immunosuppressive complications were
assumed to be $600 and $6500 per occurrence respect-
ively. Published cost data on costs for patients with
hypoglycemia unawareness, or even T1DM alone, was
scarce. We calculated costs in IIT states (with and with-
out DRC) from corrected values (see Appendix 3 in
Additional file 1) derived from a study in Ontario [33],
which reported 10 year costs of newly diagnosed dia-
betes patients with and without complications.
Utilities
We used utility measures to enable QOL adjustments of
life expectancy [37]. The highest utility was assigned to in-
sulin independence. Two studies about health-related
QOL with diabetes on type 2 and type 1 and 2 respectively
reported a mean utility value of 0.81 for diabetes without
complications [38, 39]. We assumed a “no-injection bonus”
of 0.02 and a disutility of immunosuppression of 0.01.
These led us to 0.82 for insulin independence. All other
utility weights were modelled as disutilities subtracted in-
crementally from this value. Several studies suggested an
increased health-related QOL after islet cell transplantation
[40–42] or a reduction in fear of hypoglycemia [43]. For
partial graft function we assumed a utility of 0.81 because
there is some need for insulin injections. In the first cycle
we assigned the transplantation state the same utility as
IIT. Subsequently it took the same utility value as for par-
tial graft function. We found no published evidence on the
utility decrement for severe non-self limiting hypoglycemia.
A study of T1DM found disutilities of up to 0.08 for
brief and mostly self-limiting hypoglycemia [44]. We
assumed a utility decrement of 0.10. We regard this
to be a conservative assumption because severe non-
self-limiting hypoglycemia events often require third-
party assistance.
We used a weighted average of published utility values
of seven complication disutilities to calculate the disutility
for the DRC state (Table 2) [33, 39, 45–47]. We assumed
the following mean one-time disutilities, which were sub-
tracted per occurrence from the state utilities: 0.05 for
initial complications and 0.10 per episode for major im-
munosuppressive complications. When these lasted longer
than one cycle, the disutility was applied again.
General analysis
We conducted a probabilistic analysis and structural
sensitivity analysis to investigate the cost-effectiveness of
islet cell transplantation and to evaluate uncertainty
around our results. The model was constructed and run
with the software TreeAge Pro 2015 (Williamstown,
MA, USA). Costs and benefits were discounted at 5 %
per year, as recommended by the Canadian Agency for
Drugs and Technologies in Health [48]. A half-cycle cor-
rection was applied.
We performed a probabilistic sensitivity analysis (PSA)
to incorporate parameter uncertainty by specifying each
parameter as a probability distribution rather than as a
single value known with certainty. Monte Carlo simula-
tion was used to propagate the uncertainty regarding the
model inputs through to uncertainty regarding the out-
puts (i.e., expected costs and effects of each interven-
tion). Then the incremental cost effectiveness ratios
(ICERs) were calculated using the expected costs and ef-
fects of each intervention produced by this probabilistic
analysis. In our value of information (VOI) analysis we
also calculated the expected value of perfect information
(EVPI) and the expected value of perfect parameter in-
formation (EVPPI) on both per-patient and population
levels. For information on the calculation of the popula-
tion level values see Appendix 4 (Additional file 1).
The EVPPI analysis used 600 ‘outer’ and 600 ‘inner’
loops. This setting was computationally feasible while
showing results very similar to settings with higher
numbers of loops (see Appendix 5 in Additional file
1). We also explored using a novel online tool, the
Sheffield Accelerated Value of Information (SAVI) ap-
plication [49], that estimates the EVPPI from given
sample outcomes and inputs (parameter draws) of a
PSA. We adhered to the traditional calculation ap-
proach using nested Monte Carlo simulations, since this
allowed us to calculate the EVPPI for various willingness-
to-pay levels automatically.
Our EVPPI analysis used three parameter groups:
‘costs’, ‘natural history’, and ‘effectiveness and safety’.
Those groups were chosen based on the research ve-
hicle that could be used to collect data informing the
parameters. For example, effectiveness and safety data
could be collected during a trial that is accompanied
by a patient-level QOL study, while cost data could
be collected using routine databases or micro-costing
studies. For details on each group see Appendix 6
(Additional file 1).
Currently there is no publicly adopted willingness-to-
pay threshold i.e., cost-effectiveness threshold for
Canada [50]. A study from 2015 assumed $50,000 per
QALY gained for CADTH while a threshold of
$100,000 was mentioned as early as 1993 [51, 52]. We
used both thresholds because we considered $50,000
the more conventional figure and $100,000 the upper
limit. Some results at $50,000 were not reported if they
are zero or directly follow from our conclusions at
$100,000.
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Scenario analysis
We used scenario analyses to consider the impact on the
ICERs of different discount rates, unit costs of immuno-
therapy, mortality rates and disutilities in the IIT states.
We examined the impact of assuming (a) 10 year and
(b) 14 year reductions in life expectancy. The presumed
disutilities of being in the IIT states with and without
complications, both of which translate in potential QOL
gains through transplantation, could be seen as conser-
vatively small. That is why we looked at the effect of
doubling both disutilities. This meant using mean util-
ities of 0.43 and 0.61 for the IIT states with and without
complications respectively. Also we took a preliminary
look at some hypothetical scenarios. In one scenario,
there was no need for immunosuppressive medication.
In another one there was reduction of $20,000 in the
cost per transplantation.
Further, we explored the effects of using different costs
in the IIT states with and without DRC. This was neces-
sary because (a) the data in our source study from On-
tario pointed towards costs that rise with the number of
years a patient has diabetes, and (b) our patient group
had diabetes for a longer time than the patient group in
the source study. We tried to implement the rising costs
by using tunnel states for DRC and IIT states, but found
this to raise costs slightly and increase model running
time more than 40-fold. Therefore, we instead multiplied
the drawn values by 1.25 and 1.10 for patients with and
without DRC respectively, giving the same result as
using tunnel states.
Results
In our base-case probabilistic analysis, the ICER for islet
cell transplantation compared with IIT was $150,006 per
QALY gained. This was calculated from expected incre-
mental per-patient cost increases of $290,816 and effects
of 1.94 QALYs. We found that transplantations led to
prolonging life by on average 3.33 years (undiscounted)
per patient and to a substantial increase in quality of life.
The latter follows from the incremental figures for
QALYs being higher than the corresponding life years
figures in Table 4, which shows the main results for
different sub model scenarios.
In all simulations and scenarios, islet cell transplant-
ation was more effective but more costly than IIT. At a
willingness-to-pay for each additional QALY (WTP) of
$50,000 ($100,000) the incremental net monetary benefit
of islet cell transplantation was negative (-) $193,881
(-$96,946). Treatment was more costly than IIT even
when looking only at costs occurring after the first year.
The probability that islet cell transplantation is cost-
effective reached 95 % at a WTP of $196,000 and it fell
to 13 % at a WTP of $125,000 and 0.5 % at a WTP of
$100,000.
Results differed for sub models (Figs. 2 and 3 and
Table 4). The lowest ICER for islet cell transplantation
($63,668 per QALY) was found when we assumed gen-
eric immunosuppression and a 1 % discount rate. In this
scenario the probability of being cost-effective at a WTP
of $50,000 or $100,000 was 9.5 % or 99.2 % respectively.





























Willingness-to-pay threshold (thousand $ per QALY) 
Cost-Effectiveness Acceptability Curves 
Fig. 2 Cost-Effectiveness Acceptability Curves (CEACs). The probability of islet transplantation being cost-effective decreases with increasing
discount rate and rises with WTP threshold levels. The CEACs are for scenarios with different discount rates: 0 % (doted line), 3 % (short-dashed
line), 3.5 % (long-dashed line) and 5 % (solid line). The uncertainty spread around the mean cost-effectiveness increases (the curves becoming less
steep) with increasing discount rates
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the scenario that assumed a life expectancy difference of
only 10 years between our patients and the non-diabetes
population and a 5 % discount rate.
A net benefit probability map (NBPM), which shows
uncertainty contours that link the deciles in the distribu-
tion of the net health benefit results over time [53], was
plotted at a WTP of $100,000 (Fig. 4). On the map one
can see that, from a healthcare provider perspective, we
found a higher than 90 % risk that in the long-term the
net health benefit of transplantation is negative. In
addition, the map revealed that events at the beginning
of the model horizon dominated the overall variation of
the long-term results. The EVPPI results (see below)
showed the large initial spread on the NPBM was mostly
due to high variation in the cost parameters.
Scenarios analysis
Compared to the base case, the ICER was substantially
and increasingly lowered when using lower discount
rates (Table 4). While the difference between 5 and 3 %
ICERs was large (~$30,000), neither of these discount
rates led to cost-effectiveness at WTP = $100,000. Higher
discount rates implicitly favour large effects with a short
duration that occur soon over small effects with a long
duration, even if the total undiscounted effect is the
same. Although treatment benefit of islet cell transplant-
ation is typically spread out over a period of 10 to
15 years, the bulk of the extra costs of transplantation
occurs at the start of treatment. With an increasing dis-
count rate, the probability of islet cell transplantation
being net-benefit maximising decreased (Fig. 3) and the
cost-effectiveness acceptability curves became more flat,
which means the range of uncertainty around the
expected cost-effectiveness increased (Fig. 2).
Unsurprisingly, a lower disease impact on life expect-
ancy led to islet cell transplantation having lower poten-
tial and actual benefits as well as higher costs, and vice
versa (Table 4). A lower (higher) impact increased (de-
creased) the ICER by about $10,000. The scenario with
generic immunosuppression and a $20,000 reduction in
per-transplantation costs had an ICER of $90,412. Even
switching to generic immunosuppression alone lowered
incremental costs by $73,636 and the ICER to $112,023.
In the scenario with the increased cost in the IIT and
DRC states costs of both alternatives were higher but
more so in the comparator arm, leading to a slightly
lower than base case ICER of $147,573. When looking at
doubling the presumed disutilities in the IIT states we
found that this increased the cost effectiveness of islet
cell transplantation. However, our analysis found that,
even together with increased costs in the IIT states and
a 0 % discount rate, this was only enough to consider
transplantations cost-effective at a WTP of $100,000 but
not at a WTP of $50,000 (Table 4).
Value-of-information analysis
At a WTP of $100,000 the base case EVPI was $50.73
per patient and $260,744 for Alberta, assuming that
there are 5140 patients in Alberta who could potentially
benefit from the therapy (Fig. 5) [12, 14–17, 54, 55].
Using a 3 % discount rate the EVPI was $2285 per
patient and $13,44 million for Alberta. With generic im-
munosuppression those figures increased to $6480 and




























Willingness-to-pay threshold (thousand $ per QALY)
Cost-Effectiveness Acceptability Frontiers
Fig. 3 Cost-Effectiveness Acceptability Frontiers (CEAFs). The CEAFs are for scenarios with different discount rates: 0 % (doted line), 3 % (short-dashed
line), 3.5 % (long-dashed line) and 5 % (solid line). The dents in CEAFs, with their lowest points indicating the willingness-to-pay levels when islet
transplantation becomes the net benefit maximizing alternative, move to higher WTP levels when using higher discount rates
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conventional WTP of $50,000. This result was sensitive
to the choice of discount rate. When we used a discount
rate of 1 % and generic immunosuppression the EVPI at
a WTP of $50,000 was $1493 per patient and $14.34
million for Alberta. Depending on the WTP threshold
and discount rate, this means that further research into
whether islet cell transplantation is cost-effective can be
worthwhile for Alberta up to this upper limit. The value
to Canada of investing further research around islet cell
transplantation would be substantially greater, as Alberta

































Net Benefit Probability Map
Fig. 4 Net Benefit Probability Map (NBPM). Our long-term results showed a higher than 90 % risk that the long-term net health benefit of islet



























Willingness-to-pay threshold (thousand $ per QALY)
Expected Value of Perfect Information 
Fig. 5 Expected value of perfect information (EVPI). The population EVPI for scenarios with different discount rates depicted as dotted
(3 %), dashed (3.5 %) and solid (5 %) lines. With increasing discount rate the uncertainty spread is wider but the EVPI maximum is lower.
Population-level factors were adjusted for different discount rates in scenarios
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To compare the results for the parameters groups of
our EVPPI analysis we report the per-patient maximum
value for each group of parameters, that is the value at a
WTP equal to the respective ICER. That value was
$12,267 for the costs group, $11,401 for the natural his-
tory group and $8073 for the effectiveness and safety
group.
Discussion
We found that islet cell transplantation is not cost-
effective when compared to standard therapy for un-
stable T1DM. Although it shows large improvements in
health outcomes over standard therapy, as anticipated it
is also much more costly. These extra costs are not off-
set by more than proportionate improvements in health
outcomes. There is low value in obtaining further infor-
mation to reduce uncertainty in the model parameters.
Those results were found to be robust across a wide
range of alternative assumptions. However, the use of
generic immunosuppressive medication alone could
greatly improve cost-effectiveness.
Our study compared several structurally different sce-
narios giving insight into the role of key parameters in
the model. For example, we showed that one particular
model input, although independent of the treatments
under consideration, had a substantial impact on the
ICER. The discount rate was important in estimating the
net benefit of our treatment strategies. Future studies
may wish to consider including it as a ‘parameter of
interest’ for their VOI analysis.
The value of further research into the cost-effectiveness
of islet cell transplantation is dependent on lowering treat-
ment costs, the choice of discount rate and the willingness
to pay for health. Resolving the uncertainty around cost
parameters would most valuable. One purpose of our sce-
narios was to investigate the VOI implications of future
cost changes. While this study estimated the VOI only for
Alberta, the value of the public information generated
from further research there is likely to have value in
informing decision making in other jurisdictions. Hence
the value to Canada will be substantially higher and the
value to the international diabetes community greater still.
If the willingness to pay for health is substantially higher
than used in our analysis, such as the $150,000 to
$200,000 suggested by Neumann and colleagues for the
United States, then further research would be extremely
valuable and routine adoption would be a more cost-
effective use of limited healthcare resources [56].
We found two other cost-effectiveness studies that looked
at allogeneic islet cell transplantation alone (i.e., without
other transplantations) and both had IIT as comparator.
Both studies and our results show that islet cell transplant-
ation provides important improvements in health outcomes.
The first study adopted various different assumptions from
our study [57]. For example, the model assumed a 20 year
time horizon and assumed that transplantation reduced the
risk of DRC to zero. The study also assumed a much lower
age at the start of treatment (20 years), which is substantially
lower than observed in practice. Whilst the study found that
transplant could be cost saving to the system, it was driven
by graft survival assumptions which the authors acknowl-
edged to be optimistic. In addition, the distributions used to
characterise parameter uncertainty did not adhere with best
practice [20].
The second study was conducted by the Alberta-based
Institute of Health Economics (IHE) and had a series of
different model scenarios [23]. The scenario closest to
our base case showed overall results similar to those in-
dicated by our study. That lifetime sub model calculated
an ICER of $163,387 (in 2012 prices) if graft survival
completely prevented DRC. Whilst there were differ-
ences in the cohort demographic characteristics and the
costs of transplantation, the most important difference
between our study and the IHE study was the assump-
tion regarding the impact of transplantation on the risk
of diabetes-related complications. The IHE analyses
assumed in the compared scenario a much greater risk
reduction (and in other scenarios no risk reduction).
However, the impact of assuming complete prevention
of DRC on the ICER was largely offset by higher trans-
plantation costs and lower treatment costs for IIT.
A limitation of this study is that IIT and islet cell
transplantation currently cannot be considered mutually
exclusive alternate or equivalent therapies. Islet cell
transplantation is reserved as an end-stage therapy for
subjects where IIT has been offered, optimized and has
still failed to resolve risk of incapacitating and potentially
life-threatening recurrent hypoglycemic events. Never-
theless, for lack of alternatives besides transplantation,
IIT is still standard therapy for these individuals. For
those patients for which IIT has completely failed, one
can argue - aside of cost-effectiveness considerations -
that provision of islet cell transplantation is still an
appropriate use of healthcare resources, because here all
the criteria of the ‘rule of rescue’ apply [58].
Unstable T1DM has a relatively low prevalence of
about 0.1 % of the population and islet cell transplant-
ation is still a comparatively new technology. Therefore
only a limited amount of published data was available to
be used as input for model parameters. One should take
this into consideration when interpreting our results.
Additionally we based the costs for non-graft-survival
states on values from Ontario rather than Alberta. How-
ever, relevant coverage policies were found to be similar
in both provinces.
Parameter correlation was implemented only to a lim-
ited extent because of a lack of adequate data. This is a
clear limitation of our study. State costs were composite
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variables composed of relevant cost draws. The reduced
risk of DRC and the higher risk of death without graft
function were each modelled with nested two-step haz-
ard ratios. While limited parameter correlation may have
influenced our findings, it could be argued that param-
eter correlations are not as important in cohort models
as they are in individual patient simulations, thereby
limiting any impact.
Conclusions
Islet cell transplantation, although highly effective, is
currently not cost-effective due to its increased costs. Al-
though there are uncertainties in many model inputs,
the value of obtaining further information to inform a
cost-effectiveness analysis is low when currently recom-
mended discount rates are applied. If further research
were to be conducted, research about procedure and
medication-related costs would have the highest re-
search value because of the relatively large uncertainty
around those parameters and their importance in deter-
mining the current results. Further, we suggest the value
of information should not only be derived from current
data alone when knowing that this data will most likely
change in the future.
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